COVID-19 in heart transplant recipients.
Sepideh TaghaviHoda Raffiei JelodarAli RafatiAhmad AminMarzieh MirtajaddiniAhmad AminLeili ValizadehRazieh OmidvarMonireh KamaliSoroush NasehPublished in: Journal of cardiovascular and thoracic research (2022)
Introduction: After solid organ transplantation, patients require lifelong immunosuppressive medication, increasing susceptibility to COVID-19. We evaluated the clinical outcomes of heart transplant recipients in patients with COVID-19. Methods: We enrolled twenty-two COVID-19 cases of adult heart transplantation from February 2020 to September 2021. Results: The most common symptoms in patients were fever and myalgia. The death occurred in 3 (13.6 %). Conclusion: Although heart transplantation mortality may increase in the acute rejection phase concomitant with COVID-19, immunosuppressive dose reduction may not be necessary for all heart transplant patients with COVID-19.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- heart failure
- ejection fraction
- peritoneal dialysis
- stem cells
- intensive care unit
- liver failure
- risk factors
- coronary artery disease
- depressive symptoms
- respiratory syndrome coronavirus
- bone marrow
- hepatitis b virus
- respiratory failure
- adverse drug